Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors

Details for Australian Patent Application No. 2005266531 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Hunziker, Daniel; Mayweg, Alexander; Amrein, Kurt; Kuhn, Bernd; Neidhart, Werner

Agent Spruson & Ferguson

Pub. Number AU-B-2005266531

PCT Pub. Number WO2006/010546

Priority 04103639.3 28.07.04 EP

Filing date 20 July 2005

Wipo publication date 2 February 2006

Acceptance publication date 20 November 2008

International Classifications

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

C07D 213/76 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

22 February 2007 PCT application entered the National Phase

  PCT publication WO2006/010546 Priority application(s): WO2006/010546

19 April 2007 Change of Name(s) of Applicant(s), Section 104

  F. Hoffman-La Roche AG The name of the applicant has been changed to F. Hoffmann-La Roche AG

20 November 2008 Application Accepted

  Published as AU-B-2005266531

19 March 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005266534-Apparatus and method for joining a pipe conduit to a drilling device, ex- panding device, or feeding device

2005266530-Benzyltriazolone compounds as nonnucleoside reverse transcriptase inhibitors